Harrington Discovery Institute Announces 2024 Scholar-Innovator Award Recipients
2024-04-16
疫苗临床研究基因疗法
10 physician-scientists have been selected for drug development grant to advance discoveries into the clinic
CLEVELAND, April 16, 2024 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2024 class of Harrington Scholar-Innovators. The scholar awards will support breakthrough new treatments for heart disease, autoimmune disorders, cancer, infectious disease, inflammation, and rare diseases using small molecule, nucleic acid, vaccine, biologic, and gene therapies.
Harrington Discovery Institute was established in 2012 to accelerate the development of new treatments to address major unmet needs in medicine and society. Since its founding, Harrington has supported 188 drugs-in-the-making, 66 institutions, 39 company launches, 21 clinical candidates, and 15 licenses to pharma.
"Harrington Scholar-Innovators are accomplished physician-scientists whose research demonstrates innovation, creativity and the potential for clinical impact. In surrounding each scholar with an experienced pharma and business development team, we are maximizing the therapeutic potential of great science," said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Distinguished University Professor and Robert S. and Sylvia K. Reitman Family Foundation Professor of Cardiovascular Innovation at University Hospitals and Case Western Reserve University.
"This extraordinary group of physician-scientists constitutes Harrington's twelfth class of Scholar-Innovators. We are excited to help them advance their discoveries towards patients in need," said Seth Field, MD, PhD, Director, Physician-Scientist Programs and Investigator, Harrington Discovery Institute and Becky Hennessy Endowed Master Clinician in Breast Cancer Genomics.
In addition to grant funding, Harrington provides guidance and oversight in drug and business development. Harrington Scholar-Innovators also have the opportunity to compete for acceleration funds up to $300,000 and to qualify for mission-related investment funds typically up to $2MM. Scholars have facilitated access to Harrington's mission-aligned commercial entities including the Advent-Harrington Impact Fund, and to its charitable partner Morgan Stanley GIFT Cures.
The 2024 Harrington Scholar-Innovator Award recipients, their organizations and fields of research are:
Demetrios Braddock, MD, PhD – Yale University
DNA-Degrading Enzyme for the Treatment of Lupus
Christopher Holley, MD, PhD – Duke University
Non-Coding RNA to Treat Atherosclerosis
Andrew Hsieh, MD – Fred Hutchinson Cancer Research CenterCancer Research Center
Targeting mRNA Translation in Cancer
Deepak Nijhawan, MD, PhD – University of Texas Southwestern Medical Center
Oral Treatment of Glioblastoma
Russell Pachynski, MD – Washington University in St. Louis
Tumor-Targeted Therapeutic that Recruits Immune Cells
David Raleigh, MD, PhD – University of California, San Francisco
An Antibody Inhibiting NOTCH3+ Stem Cells in Meningioma
Julie Saba, MD, PhD – University of California, San Francisco
Gene Therapy for Sphingosine-1-Phosphate Lyase Insufficiency Syndrome (SPLIS)
Carlos Subauste, MD – Case Western Reserve University
Small Molecule Inhibitors of CD40 for the Treatment of Inflammatory Disorders
Jordan Winter, MD – University Hospitals Cleveland Medical Center
Targeting Wild-Type IDH1 in Pancreatic Cancer
Juliane Bubeck Wardenburg, MD, PhD – Washington University in St. Louis
Staphylococcus Aureus Vaccine to Provide Infant Protection
Harrington Discovery Institute is now accepting Letters of Intent for the
2025 Harrington Scholar-Innovator Award. The deadline to submit a brief Letter of Intent is
June 5, 2024 11:59 PM. The full application deadline, for those invited to submit, is August 7, 2024. Learn more and apply to the 2025 Scholar-Innovator Award at HarringtonDiscovery.org/Scholar-Innovators.
SOURCE Harrington Discovery Institute
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。